Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs BridgeBio Pharma Inc — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $128.28, while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ARK Autonomous Technology & Robotics ETF nearer its low. Which is the better fit depends on your goals.
| ARKQ | BBIO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $90.17 |
52-Week Low | $95.28 | $47.29 |
Market Cap | — | $16.61B |
Enterprise Value | — | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $127.85, up 3.77% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF focuses on autonomous technology and robotics, with recent news highlighting its exposure to SpaceX and defense stocks. Support and resistance levels indicate key price zones for near-term movement.
The outlook for ARKQ is supported by long-term themes in AI and robotics, though high RSI levels suggest caution. Risks include sector volatility and reliance on disruptive tech stocks. Analyst sentiment is mixed, with some recommending accumulation during dips for growth-oriented investors.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
